{"links":{"html":"https://www.erudio.com/reports/origami-5-nct07276399","json":"https://www.erudio.com/reports/origami-5-nct07276399.json","markdown":"https://www.erudio.com/reports/origami-5-nct07276399.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"origami-5-07276399"}},"request":"https://www.erudio.com/contact?report=origami-5-07276399"},"offer":{"cited_commentary_sources":23,"verified_hcp_statements":327,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":11,"optional":true,"price_per_verified_person_usd":15,"price_usd":165,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"origami-5-nct07276399"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=origami-5-07276399","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/origami-5-nct07276399","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_rule":"Deep: 301+ verified statements","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T20:12:08.221442Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":5,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":5,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":3,"title":"Primary endpoint: Objective Response Rate (ORR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)"},{"claim_count":8,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":11,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":9,"title":"Population and setting"},{"claim_count":12,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":6,"title":"The comparison"},{"claim_count":34,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":7,"title":"Safety and tolerability"},{"claim_count":10,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":8,"title":"Design and conduct"},{"claim_count":17,"coverage":"discussed","id":"A1","source_count":2,"title":"Resectability, local salvage and goals of treatment"},{"claim_count":20,"coverage":"discussed","id":"A2","source_count":6,"title":"Current alternatives and reasons to avoid or modify chemotherapy"},{"claim_count":25,"coverage":"discussed","id":"A3","source_count":12,"title":"OrigAMI-04 activity and the need for confirmation"},{"claim_count":21,"coverage":"discussed","id":"A4","source_count":8,"title":"Biological rationale, work-up and predictive biomarker needs"},{"claim_count":10,"coverage":"discussed","id":"A5","source_count":6,"title":"Administration schedules, monitoring and practical burden"},{"claim_count":10,"coverage":"discussed","id":"A6","source_count":4,"title":"Sequencing, regulatory expectations and reported access"},{"claim_count":19,"coverage":"discussed","id":"A7","source_count":5,"title":"Patient willingness, logistics and multidisciplinary support"}],"counts":{"cited_sources":23,"claims_by_expression_type":{"comparison":26,"experience":24,"interpretation":69,"opinion":91,"primary_context":2,"question":14,"restatement":62,"uncertainty":12,"unspecified":27},"claims_by_kind":{"source_observation":327},"clinician_statements":289,"evidence_units":221,"findings":11,"organisational_accounts":3,"people_cited":16,"people_identity_verified":11,"people_total":16,"screened_sources":36,"verified_claims":327},"findings_index":[{"id":"F1","structure":{"claims":18,"claims_by_group":{"comparisons":3,"experience":0,"questions":1,"restated":5,"views":9},"has_counterview":true,"limitations":3,"links":{"context":1,"support":21},"ma_question":true,"named_voices":4,"passages":15,"sources":7,"sources_by_kind":{"media":7}},"title":"The chemotherapy-backed comparison is a reason to favor enrollment for symptomatic patients—not evidence of established benefit"},{"id":"F2","structure":{"claims":19,"claims_by_group":{"comparisons":1,"experience":3,"questions":2,"restated":3,"views":10},"has_counterview":true,"limitations":3,"links":{"context":3,"support":20},"ma_question":true,"named_voices":3,"passages":15,"sources":3,"sources_by_kind":{"media":3}},"title":"Resectability and treatment goals remain gates before first-line systemic research"},{"id":"F3","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":2,"questions":1,"restated":1,"views":3},"has_counterview":true,"limitations":3,"links":{"context":2,"support":9},"ma_question":true,"named_voices":3,"passages":8,"sources":3,"sources_by_kind":{"media":3}},"title":"Lung-regimen VTE experience does not establish a head-and-neck anticoagulation requirement"},{"id":"F4","structure":{"claims":33,"claims_by_group":{"comparisons":6,"experience":1,"questions":3,"restated":9,"views":14},"has_counterview":true,"limitations":6,"links":{"context":7,"support":35},"ma_question":true,"named_voices":9,"passages":26,"sources":14,"sources_by_kind":{"commentary":3,"media":11}},"title":"Strong enthusiasm is grounded in OrigAMI-04 activity, while the first-line randomized question remains unanswered"},{"id":"F5","structure":{"claims":27,"claims_by_group":{"comparisons":2,"experience":4,"questions":0,"restated":9,"views":12},"has_counterview":true,"limitations":4,"links":{"context":2,"support":32},"ma_question":true,"named_voices":5,"passages":19,"sources":7,"sources_by_kind":{"media":7}},"title":"The existing alternatives include justified reasons to omit, retain or change chemotherapy"},{"id":"F6","structure":{"claims":31,"claims_by_group":{"comparisons":1,"experience":2,"questions":0,"restated":7,"views":21},"has_counterview":true,"limitations":4,"links":{"context":4,"support":33},"ma_question":true,"named_voices":7,"passages":28,"sources":10,"sources_by_kind":{"media":10}},"title":"HPV-negative unmet need and EGFR/MET biology support development, not validated agent matching"},{"id":"F7","structure":{"claims":27,"claims_by_group":{"comparisons":9,"experience":4,"questions":0,"restated":5,"views":9},"has_counterview":true,"limitations":4,"links":{"context":2,"support":29},"ma_question":true,"named_voices":5,"passages":20,"sources":9,"sources_by_kind":{"media":9}},"title":"Subcutaneous delivery is attractive, but reaction risk, visit burden and combination experience remain qualified"},{"id":"F8","structure":{"claims":20,"claims_by_group":{"comparisons":1,"experience":2,"questions":0,"restated":1,"views":16},"has_counterview":true,"limitations":4,"links":{"context":1,"support":21},"ma_question":true,"named_voices":4,"passages":10,"sources":5,"sources_by_kind":{"media":5}},"title":"Proactive toxicity care is central to feasibility, with limits on extrapolation and monitoring generalization"},{"id":"F9","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":3,"questions":2,"restated":3,"views":8},"has_counterview":true,"limitations":5,"links":{"context":2,"support":18},"ma_question":true,"named_voices":5,"passages":12,"sources":6,"sources_by_kind":{"media":6}},"title":"Sequencing preferences are conditional, while reported later-line access is distinct from approval"},{"id":"F10","structure":{"claims":25,"claims_by_group":{"comparisons":0,"experience":4,"questions":3,"restated":3,"views":15},"has_counterview":true,"limitations":3,"links":{"context":0,"support":27},"ma_question":true,"named_voices":5,"passages":12,"sources":5,"sources_by_kind":{"media":5}},"title":"Trial suitability includes patient willingness, practical access and sustained multidisciplinary support"},{"id":"F_RM_STANDARD_CARE_CONTEXT","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":2,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Routine-care alternatives qualify interest in the first-line trial"}],"medical_affairs_question":"Which patients need the chemotherapy-backed research option rather than monotherapy or local salvage, and what evidence and supportive care would justify changing practice?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. Why the chemotherapy-backed comparison matters"},{"id":"section-2","level":2,"title":"2. Local salvage is not displaced by an appealing systemic option"},{"id":"section-3","level":2,"title":"3. The anticoagulation exchange contains a material scope correction"},{"id":"section-4","level":2,"title":"4. What the precursor activity does—and does not—establish"},{"id":"section-5","level":2,"title":"5. Reasons not to default to chemotherapy intensification"},{"id":"section-6","level":2,"title":"6. Biological plausibility, prognostic work-up and unresolved selection"},{"id":"section-7","level":2,"title":"7. Route-specific advantages do not remove treatment burden"},{"id":"section-8","level":2,"title":"8. Proactive care extends beyond administration reactions"},{"id":"section-9","level":2,"title":"9. Sequencing, availability and access answer different questions"},{"id":"section-10","level":2,"title":"10. Practical suitability and support can determine whether enrollment is realistic"},{"id":"section-11","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F9","shared_claims":1}],"id":"T1","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F5","shared_claims":1},{"id":"F9","shared_claims":1}],"id":"T2","label":"Primary endpoint: Objective Response Rate (ORR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":6},{"id":"F8","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":5},{"id":"F9","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":9},{"id":"F5","shared_claims":4}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":5},{"id":"F7","shared_claims":16},{"id":"F8","shared_claims":17}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":5},{"id":"F6","shared_claims":2},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":1},{"id":"F9","shared_claims":2}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T20:12:08.221442Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T20:24:14Z","record_hash":"ee9299f99f96cbaa44d1484295a948ccc10e15f27ac3b45a3a90397f83bc7e6f","release_hash":"c224a47ee6fc216fea2aa9a6a59b77693cb0507dfa452829f1cddc1ad8a5fe4e","report_id":"erudio-nct07276399","run_id":"16eed1d5-49ae-4c10-ae03-4ac8dfb87977","schema_version":"5.0","slug":"origami-5-07276399","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"OrigAMI-5 tests whether amivantamab, carboplatin and pembrolizumab improve response and survival versus platinum, 5-FU and pembrolizumab in first-line HPV-negative recurrent/metastatic head and neck squamous cell cancer. Commentary includes podcasts and YouTube discussions with medical oncologists and nurse practitioners, alongside X posts. The discussion turns on conditional preferences for OrigAMI-5 enrollment and whether amivantamab has a first-line role, which remains unresolved despite enthusiasm for OrigAMI-04 activity.","meta_description":"36 sources screened · 327 verified statements (289 from clinicians verified by NPI or staff page) from 23 sources · 11 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-da8dbb157c714011fbc8"],"id":"F4","paraphrase":"A YouTube panel addresses how to interpret earlier amivantamab response findings and what evidence is needed to assess its role in first-line treatment.","publication_caveats":{"reason":"Publication-specific caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"youtube","source_date":"2026-06-02","title":"Strong enthusiasm is grounded in OrigAMI-04 activity, while the first-line randomized question remains unanswered"},{"cited_claim_ids":["claim-04254d2e708e4450a5a7"],"id":"F1","paraphrase":"A physician in a YouTube discussion addresses how trial comparators enter enrollment decisions for symptomatic patients considering first-line treatment.","publication_caveats":{"reason":"Publication-specific caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"youtube","source_date":"2026-02-19","title":"The chemotherapy-backed comparison is a reason to favor enrollment for symptomatic patients—not evidence of established benefit"}]},"publication":{"approved_at":"2026-10-31T20:24:14Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":36},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on limitations of target-lesion-based response assessment in recurrent/metastatic head and neck cancer.","Not yet captured in this edition: a remark on the trial’s launch, untreated HPV-unrelated recurrent/metastatic population and randomized treatment comparison.","Not yet captured in this edition: a view on patient selection for first-line treatment of recurrent head and neck cancer after prior definitive therapy.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","178 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion. Educational sessions can appear in multiple formats, and posts may relay the same underlying remarks.","Coverage favored trial identifiers and names. Discussions of the same clinical decision without those references, including older discussions, may be underrepresented, and some potentially relevant passages were not fully assessed.","No full protocol or exact-trial results publication was available for this report. The drug's regulatory context was not comprehensively assessed, so reported eligibility, dosing, monitoring and approval expectations are not confirmed protocol or regulatory rules.","Most efficacy enthusiasm concerns OrigAMI-04 or other early clinical experience, often single-arm, small and compared with historical expectations. It cannot establish OrigAMI-5 comparative benefit or harm.","Source publication dates can differ from session or presentation dates. Differences between dated accounts do not by themselves demonstrate a change of mind.","Some passages cannot be assigned to a named speaker. Program titles, participant lists and professional profiles do not resolve who spoke those passages.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","PD-L1 eligibility accounts differ, and one combination-experience assertion sits alongside discussion of an amivantamab–paclitaxel cohort. These statements are preserved as expressed rather than silently reconciled.","A compressed complete-response comparison leaves the ownership of a 15% figure unclear, and reported reaction rates and observation practices concern different cohorts or settings.","Detailed strategies for populations outside the HPV-negative/HPV-unrelated first-line decision are not developed in this narrative; their statements remain available separately.","The forthcoming frontline cohort-5 triplet account and parts of the alternative-bispecific efficacy and response-durability discussion are not fully covered here. Comparisons among these options therefore remain incomplete."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":4,"publication":0,"registry":0,"regulatory":0,"x_thread":8,"x_video":1,"youtube":9},"by_evidence_role":{"commentary":23},"count":23,"evidence_window":{"end":"2026-10-25","start":"2025-10-19"},"retrieval_snapshot":"2026-10-31T14:02:01.248033Z","timeline":[{"count":4,"week":"2025-W42"},{"count":4,"week":"2025-W43"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2025-W46"},{"count":2,"week":"2025-W50"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W11"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":2,"week":"2026-W29"},{"count":2,"week":"2026-W43"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07276399:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07276399:context","quote_policy":"short_quote_link_out"},{"id":"openfda:1466c070-9f97-4fa4-a955-6a6b59981fb8:20251111","quote_policy":"short_quote_link_out"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"openfda:4c89cedc-e48b-445c-ad05-54dbe60e4fb0:20260721","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4tmmk5seuscsxev3tjgbyv4z-3mn3yosjbh22n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mg4ai2ihdc2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mg5x6q426s2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-fmv5jqznt2yvxyeuscji3khp-3m3v327w4hk26","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:41a13b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:4a9d9d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5ddaa0","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8251cf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979929570242642081:38fc611a-0cbf-428d-afdb-d2f298ecee50","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979929663213637715:d32fadbf-fc2a-4f7b-8fa1-787bc96b51ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979934871045939337:78a0d609-2940-4434-9545-7944d715b348","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979938716895662258:19a18eef-91ce-40e3-8962-09eccf218a87","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979962949142781972:38c719db-0d74-48b0-aaf8-cc7453df122c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980229837601308768:ea1edbf2-c699-4e70-aea3-d6cb29a19c43","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981100419054260289:1db1c5ae-3ba4-46a7-9f59-c68dbf13e2cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981427809269538874:a7f2434b-8b60-40a4-a3a0-0c286c7f151e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981544253198389415:d8f9311a-bf1b-4d74-9da0-4bc5c09c9da5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1990480376221880759:6735b792-e44b-4793-a50e-7c10151bce51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2000696553007190284:81b55cb1-173f-4f4f-8fbe-32555f5923a8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001383371960623444:b04923c9-4127-46ea-8581-86b51085e9bb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2002131177491386711:1b2a2321-23b0-436d-8f54-a2759fc290a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2028589265706176909:80cf1b8b-f304-414c-9bf0-a17f01d0895c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2028818927170584836:ba1431a9-cce3-4ea4-b69b-e6d54d04ff26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053468630390567155:c97133b7-687a-4041-99b0-47d748e5aab1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2071255093895143917:7a8de289-7c2b-47bf-8f9f-30f34cebbee5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2075613827580719250:2325def5-f412-4870-a068-2546162fff84","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1984195468465721707","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4eH2dkAXYC8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:FSGbIaz7pbA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:FglDPIy4VhI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:GdhFyBh8Nc0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:NfYu8jCUa6A","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SfPRPVb3qPU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:pKeg_MG4DI0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:qpTaOW7psGM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:rIfF2S4AvZo","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":0,"other":0,"podcast":4,"publication":0,"registry":0,"regulatory":0,"x_thread":18,"x_video":1,"youtube":9},"by_evidence_role":{"commentary":36},"count":36,"evidence_window":{"end":"2026-10-25","start":"2025-10-19"},"retrieval_snapshot":"2026-10-31T14:02:01.248033Z","timeline":[{"count":5,"week":"2025-W42"},{"count":6,"week":"2025-W43"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W47"},{"count":2,"week":"2025-W50"},{"count":3,"week":"2025-W51"},{"count":1,"week":"2026-W08"},{"count":5,"week":"2026-W10"},{"count":1,"week":"2026-W11"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W20"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W26"},{"count":1,"week":"2026-W28"},{"count":2,"week":"2026-W29"},{"count":2,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Rybrevant"],"label":"amivantamab","slug":"amivantamab"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"reason":"Unmapped registry intervention: 5-flurouracil","status":"unmapped"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"}],"indications":[{"reason":"Unmapped registry condition: Squamous Cell Carcinoma of Head and Neck","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"OrigAMI-5","aliases":["OrigAMI-5","A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma"],"brief_title":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Squamous Cell Carcinoma of Head and Neck"],"display_condition":"treatment-naïve recurrent/metastatic head and neck squamous cell carcinoma","display_interventions":[["amivantamab","pembrolizumab"]],"enrollment":{"count":500,"type":"ESTIMATED"},"interventions":[{"name":"Amivantamab","synonyms":["JNJ-61186372","RYBREVANT"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"5-Flurouracil","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07276399","official_title":"A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2029-06-18","type":"ESTIMATED"},"primary_endpoints":[{"description":"OS is defined as time from the date of randomization to the date of death due to any cause.","measure":"Overall Survival (OS)","timeFrame":"Up to approximately 3 years 7 months"},{"description":"ORR is defined as the percentage of randomized participants achieving a confirmed best overall response (BOR) of partial response (PR) or complete response (CR) by BICR using RECIST version 1.1 .","measure":"Objective Response Rate (ORR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 3 years 7 months"}],"registered_date":{"date":"2025-12-11","type":"ACTUAL"},"registry_last_updated":"2026-09-25","registry_url":"https://clinicaltrials.gov/study/NCT07276399","short_name":"OrigAMI-5","short_name_basis":"registry_acronym","sponsor":"Janssen Research & Development, LLC","start_date":{"date":"2025-12-03","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"61186372HNC3001","type":"sponsor_study_id"},{"domain":"EUCT number","id":"2025-521917-24-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}